RESUMEN
PURPOSE: Detection of regional cerebral blood flow (rCBF) and/or brain magnetic resonance imaging (MRI) has been used to investigate functional defect of brain caused by carbon monoxide (CO) poisoning. In this report, we attempted to demonstrate the correlation of changes in brain singlephoton emission computed tomography (SPECT) and diffusion-tensor MR image (DTI) with functional improvement of severe delayed neuropsychiatric sequelae (DNS) after CO intoxication during the treatment of hyperbaric oxygen therapy (HBOT). CASE REPORT: The patient had normal activities of daily life after he recovered from acute CO poisoning. One month later, he presented symptoms of declined cognitive functioning, aphasia, apraxia, dysphagia, muscle rigidity, urine and fecal incontinence. After one course of HBOT, these symptoms improved significantly and the patient could regain most of his previous functioning. The patient's improvement was evidenced by increased rCBF in Brodmann areas 7, 8, 11 and 40, as well as higher mean fractional anisotropy (FA) value of DTI. CONCLUSION: Although the efficacy of HBOT in DNS patients is still needed to be evaluated in large clinical study, these data suggest that HBOT may be the choice to improve DNS efficiently and shorten the duration of suffering with favorable outcome.
Asunto(s)
Apraxias/prevención & control , Intoxicación por Monóxido de Carbono/terapia , Trastornos del Conocimiento/prevención & control , Trastornos de Deglución/prevención & control , Oxigenoterapia Hiperbárica , Rigidez Muscular/prevención & control , Adulto , Apraxias/inducido químicamente , Intoxicación por Monóxido de Carbono/complicaciones , Circulación Cerebrovascular/fisiología , Trastornos del Conocimiento/inducido químicamente , Trastornos de Deglución/inducido químicamente , Imagen de Difusión Tensora , Incontinencia Fecal/inducido químicamente , Incontinencia Fecal/prevención & control , Humanos , Masculino , Rigidez Muscular/inducido químicamente , Tomografía Computarizada de Emisión de Fotón Único , Resultado del Tratamiento , Incontinencia Urinaria/inducido químicamente , Incontinencia Urinaria/prevención & controlRESUMEN
The symptoms and lethality of intoxication with the acetylcholinesterase inactivator soman are attributed primarily to excessive activation of muscarinic acetylcholine receptors; nicotinic activation is considered of less importance, a notion that may rely on studies that have used nicotinic antagonists at low doses. In this study pretreatment with the centrally acting nicotinic antagonist mecamylamine, 20mg/kg, but not 2mg/kg, prolonged survival in mice exposed to soman, 250 microg/kg (1.5 LD(50)), from 14+/-3 to 135+/-38 min (mean+/-S.E.M.; surviving animals were killed 240 min after soman administration). Pretreatment with the muscarinic blocker scopolamine, 2 or 20mg/kg (but not 0.5mg/kg) prolonged survival significantly (mean for both groups: 91 min), but the animals responded to soman with immobility, irregular respiration, fasciculation, and short episodes of convulsive crawling. These symptoms were absent in animals pretreated with scopolamine plus mecamylamine, both drugs 20mg/kg, a suggestion that they were caused by activation of nicotinic receptors. All animals pretreated with scopolamine and mecamylamine (both drugs 20 mg/kg) survived the full 240 min observation period. Administration of mecamylamine, 5 mg/kg, 5 min after soman exposure to scopolamine-pretreated animals reduced fasciculation and respiratory irregularity and prolonged survival compared to scopolamine alone, but mecamylamine, 20 mg/kg, given 10 min after soman exposure shortened survival (18+/-1 min). These results suggest that nicotinic activation plays an important part in soman-induced symptomatology and lethality but also that nicotinic antagonists given in large doses after soman exposure may have untoward effects.
Asunto(s)
Sustancias para la Guerra Química/toxicidad , Nicotina/farmacología , Intoxicación , Soman/toxicidad , Acetilcolinesterasa/metabolismo , Análisis de Varianza , Animales , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Femenino , Hipercinesia/inducido químicamente , Hipercinesia/prevención & control , Dosificación Letal Mediana , Mecamilamina/administración & dosificación , Ratones , Antagonistas Muscarínicos/administración & dosificación , Rigidez Muscular/inducido químicamente , Rigidez Muscular/prevención & control , Antagonistas Nicotínicos/administración & dosificación , Intoxicación/etiología , Intoxicación/fisiopatología , Intoxicación/prevención & control , Escopolamina/administración & dosificación , Factores de Tiempo , Temblor/inducido químicamente , Temblor/prevención & controlRESUMEN
A method is described to detect selective alpha-2 adrenergic agonists in vivo. Palpebral ptosis is induced in rats by the neuroleptic agent haloperidol (Hal), or by tetrabenazine (TBZ) methanesulfonate. Twenty minutes later, test compounds are injected, and ptosis is scored. In a separate test, muscular rigidity is induced by the opioid, fentanyl, and subsequently, test compounds are assessed for their ability to reverse muscular rigidity. Results indicate that only alpha-2 agonists reliably reverse neuroleptic-induced and TBZ-induced ptosis, as well as opioid-induced rigidity. An alpha-1 antagonist reversed only rigidity, whereas, alpha-2 antagonists and beta-agonists were generally ineffective in all tests. Therefore, the ability to reverse neuroleptic and TBZ-induced ptosis along with the ability to reverse opioid-induced muscular rigidity is a characteristic unique to alpha-2 agonists.